The Valley Desk

NCT00364858 · Interventional trial

Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease

Overall registry status Completed

Phase 4

Conditions Cerebroside Lipidosis Syndrome, Gaucher Disease, Non-Neuronopathic Form, Gaucher Disease, Type 1, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov